Travere Q2: FILSPARI Sales Surge 96%, FSGS Approval, and a $1B+ Pipeline Deal
TVTX has more than doubled off its 52-week low of $15.42.
Summary
Travere Therapeutics reported Q2 2026 FILSPARI sales of $141.1M (up 96% YoY), secured FDA approval for FSGS, restarted a key Phase 3 trial, raised $525M in convertible debt, and in-licensed a promising BTK inhibitor for rare kidney diseases.
Key Events · Earnings and Guidance · TVTX
-
FILSPARI Sales Surge 96%
Q2 2026 FILSPARI net sales reached $141.1 million, nearly double the $71.9 million in Q2 2025, driven by the IgAN indication and the new FSGS approval.
-
FDA Approves FILSPARI for FSGS
On April 13, 2026, the FDA granted full approval of FILSPARI to reduce proteinuria in FSGS patients aged 8 and older without nephrotic syndrome, making it the first and only approved therapy for FSGS.
-
Phase 3 HARMONY Study Restarts
Enrollment in the pivotal Phase 3 HARMONY Study of pegtibatinase for classical HCU resumed in Q1 2026 after a voluntary pause to address manufacturing scale-up; the first new patient was dosed in April 2026.
-
$525M Convertible Note Offering
Travere issued $525 million of 0.50% convertible senior notes due 2032, with net proceeds of $509.3 million, and used $350.9 million to repurchase a portion of its 2029 notes, recognizing a $40.0 million non-cash inducement expense.
Analysis · TVTX · Life Sciences
Travere's Q2 2026 results mark a turning point. FILSPARI net sales hit $141.1 million, nearly doubling year-over-year, driven by the recent FDA approval for FSGS — the first and only medicine approved for that disease. The company also restarted enrollment in the pivotal Phase 3 HARMONY Study for pegtibatinase, addressing a prior manufacturing setback. Financially, Travere completed a $525 million convertible note offering and used part of the proceeds to repurchase older notes, strengthening the balance sheet but adding potential dilution. The quarter's biggest strategic move is the exclusive license for civorebrutinib, a BTK inhibitor with proof-of-concept in membranous nephropathy, which could become a pipeline-in-a-product across multiple rare kidney diseases. The deal commits Travere to a $112.5 million upfront payment and up to $1.03 billion in milestones. While the company is still unprofitable, the revenue trajectory and pipeline expansion signal a biotech transitioning from development to commercial execution.
At the time of this filing, TVTX was trading at $63.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $15.42 to $60.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.